Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Inge, Lefevre"'
Autor:
Inge LeFevre, Lulu Bravo, Nicolas Folschweiller, Eduardo Lopez Medina, Edson Duarte Moreira, Francesco Nordio, Mayuri Sharma, Leslie M. Tharenos, Vianney Tricou, Veerachai Watanaveeradej, Peter J. Winkle, Shibadas Biswal
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-9 (2023)
Abstract Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosq
Externí odkaz:
https://doaj.org/article/37a0af7ecf4841298de437faee7ed315
Autor:
Sanjay S. Patel, Peter Winkle, Alice Faccin, Francesco Nordio, Inge LeFevre, Claudia Galindo Tsoukas
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®),
Externí odkaz:
https://doaj.org/article/50b950bd413f434ea8be3b20f2fe6d42
Autor:
Vianney Tricou, Brandon Essink, John E Ervin, Mark Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski, Derek Wallace
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 3, p e0011124 (2023)
BackgroundYellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individual
Externí odkaz:
https://doaj.org/article/c6f7122f93b84fdc87e18dd196662f44
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
Autor:
Shibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Esteban Patricio Rodriguez Bueno, Manja Brose, Martina Rauscher, Inge LeFevre, Derek Wallace, Astrid Borkowski
Publikováno v:
Revista Panamericana de Salud Pública, Vol 45, Iss 67, Pp 1-11 (2021)
Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. Participants aged 12–17 years were random
Externí odkaz:
https://doaj.org/article/3e634197f1df46e6bd0517825679a613
Autor:
Xavier Sáez-Llorens, Shibadas Biswal, Charissa Borja-Tabora, LakKumar Fernando, Mengya Liu, Derek Wallace, Nicolas Folschweiller, Humberto Reynales, Inge LeFevre
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 108:722-726
In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue between the first dose and the end of the study, ∼57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aea448a41c312f5b9a3fd7c6f519bbc
https://doi.org/10.4269/ajtmh.22-0673
https://doi.org/10.4269/ajtmh.22-0673
Autor:
Vianney Tricou, Susannah Eyre, Mahadev Ramjee, Paul Collini, Zenaida Mojares, Edde Loeliger, Sanja Mandaric, Martina Rauscher, Manja Brose, Inge Lefevre, Nicolas Folschweiller, Derek Wallace
Publikováno v:
Vaccine. 41:1398-1407
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0039d30ae1633561d007c9c2bff1de2
https://doi.org/10.1016/j.vaccine.2023.01.007
https://doi.org/10.1016/j.vaccine.2023.01.007
Autor:
Felix Espinoza, Edson D. Moreira, Inge Lefevre, Maria Theresa Alera, Asvini D. Fernando, Mengya Liu, Delia Yu, Pope Kosalaraksa, Luis Rivera, Vianney Tricou, Martina Rauscher, Hector Velásquez, Pujitha Wickramasinghe, Dulanie Gunasekera, Derek Wallace, Lulu Bravo, Luis Martinez Vargas, Xavier Sáez-Llorens, Rivaldo Venâncio da Cunha, Veerachai Watanaveeradej, Astrid Borkowski, Charissa Borja-Tabora, Kleber Giovanni Luz, Edith Johana Rodriguez-Arenales, Chukiat Sirivichayakul, Reynaldo Dietze, Shibadas Biswal, Humberto Reynales, Eduardo López-Medina, LakKumar Fernando
Publikováno v:
The Journal of Infectious Diseases. 225:1521-1532
Background Takeda’s dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 months apart and are und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75449e4aaa1a1f69e884a4d800744c8a
https://doi.org/10.1093/infdis/jiaa761
https://doi.org/10.1093/infdis/jiaa761
Autor:
Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas, Hector Velásquez, Maria Theresa Alera, Victor Sierra, Edith Johana Rodriguez-Arenales, Delia Yu, V Pujitha Wickramasinghe, Edson Duarte Moreira, Asvini D Fernando, Dulanie Gunasekera, Pope Kosalaraksa, Felix Espinoza, Eduardo López-Medina, Lulu Bravo, Suely Tuboi, Yanee Hutagalung, Pedro Garbes, Ian Escudero, Martina Rauscher, Svetlana Bizjajeva, Inge LeFevre, Astrid Borkowski, Xavier Saez-Llorens, Derek Wallace, Alys Concepción, Ana Cecilia Villarreal, Asvini Fernando, Chukiat Sirivichayakul, Edith Johanna Rodriguez-Arenales, Humberto Reynales, Kleber Luz, Jose Jimeno, LakKumar Fernando, Luis Rivera, Onanong Manacharoen, Pio Lopez, V. Pujitha Wickramasinghe, Reynaldo Dietze, Rivaldo Venâncio da Cunha, Veerachai Watanaveeradej, Manja Brose, Kelley Moss, Seetha Meyer, Vianney Tricou
Publikováno v:
The Lancet. 395:1423-1433
A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live att
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbc3a1aa1e559a6eb34d4833afa34af3
https://doi.org/10.1016/s0140-6736(20)30414-1
https://doi.org/10.1016/s0140-6736(20)30414-1
Autor:
Shibadas, Biswal, Humberto, Reynales, Xavier, Saez-Llorens, Pio, Lopez, Charissa, Borja-Tabora, Pope, Kosalaraksa, Chukiat, Sirivichayakul, Veerachai, Watanaveeradej, Luis, Rivera, Felix, Espinoza, LakKumar, Fernando, Reynaldo, Dietze, Kleber, Luz, Rivaldo, Venâncio da Cunha, José, Jimeno, Eduardo, López-Medina, Astrid, Borkowski, Manja, Brose, Martina, Rauscher, Inge, LeFevre, Svetlana, Bizjajeva, Lulu, Bravo, Derek, Wallace, Zenaida, Mojares
Publikováno v:
New England Journal of Medicine. 381:2009-2019
Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb379596b39c33f8244e193620a0acb
https://doi.org/10.1056/nejmoa1903869
https://doi.org/10.1056/nejmoa1903869
Autor:
Shibadas Biswal, Reynaldo Dietze, Martina Rauscher, Mengya Liu, Delia Yu, Inge Lefevre, Humberto Reynales, Luis Rivera, Vianney Tricou, Eduardo López-Medina, Pope Kosalaraksa, Lulu Bravo, Charissa Borja-Tabora, Chukiat Sirivichayakul, Edson D. Moreira, Dulanie Gunasekera, Astrid Borkowski, Luis Vargas, Maria Theresa Alera, Derek Wallace, Veerachai Watanaveeradej, Kleber Giovanni Luz, Lakkumar Fernando, Xavier Sáez-Llorens, Rivaldo Venâncio da Cunha, Elaine Hoffman, Pujitha Wickramasinghe, Felix Espinoza, Olaf Zent, Asvini D. Fernando
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(1)
Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in both seronegative and se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a10cb2390bfd2dafd61e84a89f26346
https://pubmed.ncbi.nlm.nih.gov/34606595
https://pubmed.ncbi.nlm.nih.gov/34606595